Список литературы

1. Carbone P.P. et al. Report of the Committee on Hodgkin's Disease Staging Classification//Cancer Res. 1971. Vol. 31, N 11. P. 1860 - 1861.

2. Демина Е.А. et al. Общие принципы диагностики лимфом//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 9 - 27.

3. Воробьев В.И., Тумян Г.С. Лимфома из клеток мантии//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 68 - 80.

4. Zelenetz A.D. et al. B-cell lymphomas. NCCN Clinical Practice Guidelines in Oncology. Version 5. 2019.

5. Dreyling M. et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up//Ann. Oncol. 2017. Vol. 28, N Supplement 4. P. iv62 - iv71.

6. Gill S. et al. [18F]Fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma//Clin. Lymphoma Myeloma. Cancer Information Group, LP, 2008. Vol. 8, N 3. P. 159 - 165.

7. Sun T. et al. Fluorescence in situ hybridization: method of choice for a definitive diagnosis of mantle cell lymphoma.//Am. J. Hematol. 2003. Vol. 74, N 1. P. 78 - 84.

8. Alavi A. et al. Fluorodeoxyglucose-positron-emission tomography findings in mantle cell lymphoma//Clin. Lymphoma, Myeloma Leuk. 2011. Vol. 11, N 3. P. 261 - 266.

9. Swerdlow S.H. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC)/ed. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H T.J. 2017. 585 p.

10. Howard O.M. et al. Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival//J. Clin. Oncol. 2002. Vol. 20, N 5. P. 1288 - 1294.

11. LaCasce A.S. et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.//Blood. 2012. Vol. 119, N 9. P. 2093 - 2099.

12. Lenz G. et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantiy improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)//J. Clin. Oncol. 2005. Vol. 23, N 9. P. 1984 - 1992.

13. Bernstein S.H. et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213//Ann. Oncol. 2013. Vol. 24, N 6. P. 1587 - 1593.

14. Damon L.E. et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909//J. Clin. Oncol. 2009. Vol. 27, N 36. P. 6101 - 6108.

15. Dreyling M. et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.//Blood. 2005. Vol. 105, N 7. P. 2677 - 2684.

16. Fenske T.S., Carreras T., Zhang M. Outcome of patients with mantle-cell lymphoma undergoing autologous versus reduced-intensity allogenic transplantation//Ann. Oncol. 2011. Vol. 22, N Suppl. 4. P. Abstract 018.

17. Visco C. et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation//J. Clin. Oncol. 2013. Vol. 31, N 11. P. 1442 - 1449.

18. Rummel M.J. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial//Lancet. Lancet Publishing Group, 2013. Vol. 381, N 9873. P. 1203 - 1210.

19. Geisler C.H. Front-line therapy of mantle cell lymphoma//Haematologica. 2010. Vol. 95. P. 1241 - 1243.

20. Kluin-Nelemans H.C. et al. Treatment of older patients with mantle-cell lymphoma//N. Engl. J. Med. Massachussetts Medical Society, 2012. Vol. 367, N 6. P. 520 - 531.

21. Kahl B.S. et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: A pilot study from the Wisconsin Oncology Network//Ann. Oncol. 2006. Vol. 17, N 9. P. 1418 - 1423.

22. Hilal T. et al. Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis.//Am. J. Hematol. 2018. Vol. 93, N 10. P. 1220 - 1226.

23. Rule S. et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.//Br. J. Haematol. 2017. Vol. 179, N 3. P. 430 - 438.

24. Ruan J. et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma//Blood. American Society of Hematology, 2018. Vol. 132, N 19. P. 2016 - 2025.

25. Romaguera J.E. et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.//Br. J. Haematol. 2010. Vol. 150, N 2. P. 200 - 208.

26. Martin P. et al. Outcome of deferred initial therapy in mantle-cell lymphoma//J. Clin. Oncol. 2009. Vol. 27, N 8. P. 1209 - 1213.

27. Hermine O. et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network//Lancet. Lancet Publishing Group, 2016. Vol. 388, N 10044. P. 565 - 575.

28. Merli F. et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi.//Br. J. Haematol. 2012. Vol. 156, N 3. P. 346 - 353.

29. Chihara D. et al. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.//Br. J. Haematol. 2016. Vol. 172, N 1. P. 80 - 88.

30. Geisler C.H. et al. Nordic MCL2 trial update: Six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: Still very long survival but late relapses do occur//Br. J. Haematol. 2012. Vol. 158, N 3. P. 355 - 362.

31. Eskelund C.W. et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.//Br. J. Haematol. 2016. Vol. 175, N 3. P. 410 - 418.

32. Pott C. et al. R-CHOP/R-DHAP Compared to R-CHOP Induction Followed by High Dose Therapy with Autologous Stem Cell Transplantation Induces Higher Rates of Molecular Remission In MCL: Results of the MCL Younger Intergroup Trial of the European MCL Network//Blood. 2010. Vol. 116, N 21.

33. Le Gouill S. et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma//N. Engl. J. Med. Massachussetts Medical Society, 2017. Vol. 377, N 13. P. 1250 - 1260.

34. Hoster E., Pott C. Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment.//Hematol. Am. Soc. Hematol. Educ. Progr. 2016. Vol. 2016, N 1. P. 437 - 445.

35. Cheminant M. et al. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study.//Haematologica. 2016. Vol. 101, N 3. P. 336 - 345.

36. Gatt M.E., Grisaro S. Central nervous system prophylaxis in mantle cell lymphoma//Blood. American Society of Hematology, 2009. Vol. 114, N 26. P. 5402 - 5403.

37. Crocchiolo R. et al. Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients//Haematologica. Ferrata Storti Foundation, 2015. Vol. 100, N 10. P. e423 - e427.

38. Dreyling M. et al. Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations//Leuk. Lymphoma. Taylor and Francis Ltd, 2018. Vol. 59, N 8. P. 1814 - 1828.

39. Weigert O. et al. High Dose Cytarabine Salvage Regimen Combined with Bortezomib Is Feasible and Highly Effective in Relapsed Mantle Cell Lymphoma.//Blood. 2006. Vol. 108, N 11. P. 2449 - 2449.

40. Gironella M. et al. Rituximab Plus Gemcitabine and Oxaliplatin As Salvage Therapy in Patients with Relapsed/Refractory Mantle-Cell Lymphoma//Blood. 2012. Vol. 120, N 21.

41. Corazzelli G. et al. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: Results of a pilot study//Annals of Oncology. 2006. Vol. 17, N SUPPL. 4.

42. Corazzelli G. et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.//Cancer Chemother. Pharmacol. 2009. Vol. 64, N 5. P. 907 - 916.

43. Friedberg J.W. et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma//Blood. 2011. Vol. 117, N 10. P. 2807 - 2812.

44. Wang M.L. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma//N. Engl. J. Med. Massachussetts Medical Society, 2013. Vol. 369, N 6. P. 507 - 516.

45. Wang M.L. et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results // Blood. American Society of Hematology, 2015. Vol. 126, N 6. P. 739 - 745.

46. Dreyling M. et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study//Lancet. Lancet Publishing Group, 2016. Vol. 387, N 10020. P. 770 - 778.

47. Wang M.L. et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.//Lancet. Oncol. 2016. Vol. 17, N 1. P. 48 - 56.

48. M. et al. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.//Lancet. Oncol. 2016. Vol. 17, N 3. P. 319 - 331.

49. Chong E.A. et al. Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.//Clin. Cancer Res. 2015. Vol. 21, N 8. P. 1835 - 1842.

50. Le Gouill S. et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: A multicenter experience//Ann. Oncol. 2012. Vol. 23, N 10. P. 2695 - 2703.

51. Soubeyran P., Gressin R. Treatment of the elderly patient with mantle cell lymphoma//Hematology. Bulgarian Medical Society of Hematology, 2016. Vol. 2016, N 1. P. 425 - 431.

52. Flinn I.W. et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study//Blood. American Society of Hematology, 2014. Vol. 123, N 19. P. 2944 - 2952.

53. Gressin R. et al. Frontline Therapy with the Ribvd Regimen Elicits High Clinical and Molecular Response Rates and Long PFS in Elderly Patients Mantle Cell Lymphoma (MCL); Final Results of a Prospective Phase II Trial By the Lysa Group//Blood. 2014. Vol. 124, N 21. P. 148 - 148.

54. Robak T. et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study//Lancet Oncol. Lancet Publishing Group, 2018. Vol. 19, N 11. P. 1449 - 1458.

55. Spurgeon S.E. et al. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma.//Leuk. Lymphoma. 2011. Vol. 52, N 8. P. 1488 - 1494.

56. Kluin-Nelemans H.C. et al. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial//J. Clin. Oncol. NLM (Medline), 2020. Vol. 38, N 3. P. 248 - 256.

57. Robak T. et al. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma//Cancer. 2006. Vol. 107, N 7. P. 1542 - 1550.

58. Coleman M. et al. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy.//Cancer. 2008. Vol. 112, N 10. P. 2228 - 2232.

59. Владимирова Л.Ю. et al. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных//Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии. 2018. P. 502 - 511.

60. Барях Е.А., Мякова Н.В., Поддубная И.В. Профилактика и лечение синдрома лизиса опухоли//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 251 - 253.

61. Aapro M. et al. Клинические рекомендации по лечению анемии у больных злокачественными новообразованиями. М.: Ассоциация онкологов России, 2014.

62. Орлова Р.В. et al. Практические рекомендации по лечению анемии при злокачественных новообразованиях//Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии. 2018. P. 494 - 501.

63. Абузарова Г.Р. et al. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России., 2016. 94 p.

64. Абузарова Г.Р. Лечение болевого синдрома у онкологических больных//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 278 - 288.

65. Cheson B.D. et al. Revised response criteria for malignant lymphoma//Journal of Clinical Oncology. 2007. Vol. 25, N 5. P. 579 - 586.

66. Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies.//Am. J. Phys. Med. Rehabil. 2011. Vol. 90, N 5 Suppl 1. P. S88 - 94.

67. Hoster E. et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.//Blood. 2008. Vol. 111, N 2. P. 558 - 565.

68. Schaffel R. et al. Prognostic impact of proliferative index determined by quantitative image analysis and the international prognostic index in patients with mantle cell lymphoma//Ann. Oncol. 2010. Vol. 21, N 1. P. 133 - 139.

69. Yelvington B.J. Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma.//J. Adv. Pract. Oncol. Harborside Press, 2018. Vol. 9, N 5. P. 530 - 534.

70. Davies A. et al. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development//Advances in Therapy. Springer Healthcare, 2017. Vol. 34, N 10. P. 2210 - 2231.

71. R. et al. Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study//Br. J. Haematol. Blackwell Publishing Ltd, 2020. Vol. 188, N 5. P. 661 - 673.

72. Macdonald D. et al. A canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma//Current Oncology. Multimed Inc., 2017. Vol. 24, N 1. P. 33 - 39.

73. Delarue R. et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: A phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte//Blood. American Society of Hematology, 2013. Vol. 121, N 1. P. 48 - 53.

74. Geisler C.H. et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group//Blood. 2008. Vol. 112, N 7. P. 2687 - 2693.

75. Dreyling M., Ferrero S., Hermine O. How to manage mantle cell lymphoma//Leukemia. Nature Publishing Group, 2014. Vol. 28, N 11. P. 2117 - 2130.

76. Oken M.M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group//Am. J. Clin. Oncol. 1982. Vol. 5, N 6. P. 649 - 655.